---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-034889"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:46:08.106649+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CervoMed reports Q3 2024 net loss $4.8M; cash $46.7M; RewinD-LB data due Dec 2024

## Summary
- Net loss $4.8M in Q3 2024 vs net income $2.2M in Q3 2023; R&D expenses rose to $5.1M from $1.8M.
- Cash, cash equivalents and marketable securities $46.7M at Sep 30, 2024 (vs $50.9M at Jun 30); cash runway through 2025.
- RewinD-LB Phase 2b top-line data expected Dec 2024; last patient visit Oct 2024. Plan Phase 3 mid-2025 and Phase 2a for stroke Q1 2025.
- Awarded Prix Galien USA 2024 Best Startup on Nov 8, 2024, recognizing innovation in DLB treatment development.
- Appointed Claudia Ordonez (SVP Medical) and Mark De Rosch (SVP Regulatory); granted options for 56,959 shares at $12.53.

## SEC filing metadata
- accession: 0001437749-24-034889
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774924034889/0001437749-24-034889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774924034889/crvo20241113_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-034889
- JSON: https://secwatch.observer/filing/0001437749-24-034889.json
- Plain text: https://secwatch.observer/filing/0001437749-24-034889.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.